From WisPolitics.com/WisBusiness.com …
— Lawmakers on a study committee on regulating AI in health care want rules that keep people in decision-making roles and protect patients’ data.
Sen. Rachael Cabral-Guevara, R-Fox Crossing, said she wants to hear more from medical professionals – she cited radiologists and nurses in particular – about how AI is already being incorporated into medicine, while Rep. Adam Neylon, R-Pewaukee said he wanted rules that keep practitioners in the loop as AI grows more prevalent.
“How do we ensure that maybe there are some guidelines or standards that say here in Wisconsin, we encourage AI, but there’s always a human interaction involved with our health system?” Neylon asked.
Cabral-Guevara and Neylon are the chair and vice-chair of the Legislative Council Study Committee on the Use of Artificial Intelligence in Health Care, which held its inaugural meeting yesterday.
The committee is charged with reviewing existing AI usage by providers, insurers and medical assistance programs like Medicaid and prescribing regulation governing the technology’s use.
Along with lawmakers, the study committee also includes a UW-Oshkosh lecturer, a pharmacist and executives from several health care companies, including Epic Systems and Abbott Labs.
Neylon also suggested writing regulations to protect patients’ privacy, though he acknowledged providers and insurers were already building their own proprietary tools to comply with existing privacy rules.
However, David Hoffert, AI policy director for Epic, noted that patient privacy laws had limited scope.
“HIPPA will cover the use of AI by a health care provider,” Hoffert said. “Its not going to cover your wearable, which is not a health care provider. It’s not going to cover if your patient requests their records from you and then uploads them to a large-language model.”
Rep. Mike Bare, D-Verona, suggested the committee needed to come up with a broader set of principles governing future legislation.
“We’re heading into this frontier realm that doesn’t fit very neatly into what we have regulated and legislated in the past, and that has really presented some challenges,” Bare said.
— Madison’s Elephas Biosciences Corporation has formed an agreement with Neuberg Diagnostics to bring its “elive” immunotherapy assessment platform to India.
The biotech firm, which has a “live tissue” platform for predicting the body’s response to certain cancer treatments, recently announced the exclusive partnership with India-based Neuberg Diagnostics.
The effort will bring the platform into Neuberg’s laboratory infrastructure while the company will act as Elephas’ commercial partner in India, with a goal of launching its own clinical test there by end of this year. Neuberg will also serve as research partner for Elephas in India, processing cancer biopsies at its main lab in Ahmedabad, a city in the country’s western region.
Maneesh Arora, founder and CEO of Elephas, touted Neuberg as a “recognized leader in oncology diagnostics” with a strong presence in India.
“Pairing their molecular diagnostics expertise with the elive platform lays the groundwork to bring functional immunotherapy response assessment to oncology care in India,” Arora said in a statement.
The company last month announced a similar partnership with Invitrocue, which will act as its commercial partner for extending its reach into Singapore and Malaysia, establishing a foothold in southeast Asia.
See the release below.
Top Stories
– Trump Team’s Use of Arcane Budget Rule Threatens Medicaid Coverage
– Vance urges DOJ investigation into hospitals over billing for transgender care
– US FDA approves Lantheus’ brain-imaging agent for Alzheimer’s assessment
– How many people actually have cyclosporiasis? Why it’s so hard to track
– Luigi Mangione admits killing insurance CEO, pleads guilty in federal case
– Fury at Health Insurers Persists After the Killing of a Company Executive
Press Releases
– Elephas Biosciences: Announces exclusive commercial partnership in India with Neuberg Diagnostics
